1. Grassberger C, Shinnick D, Yeap BY, et al. Circulating Lymphocyte Counts Early During Radiation Therapy Are Associated With Recurrence in Pediatric Medulloblastoma. Int J Radiat Oncol Biol Phys . Jul 15 2021;110(4):1044-1052. doi:10.1016/j.ijrobp.2021.01.035
2. Upadhyay R, Venkatesulu BP, Giridhar P, et al. Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis. Radiother Oncol . Apr 2021;157:225-233. doi:10.1016/j.radonc.2021.01.034
3. Venkatesulu B, Giridhar P, Pujari L, et al. Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy. Radiother Oncol . Dec 2022;177:81-94. doi:10.1016/j.radonc.2022.10.019
4. Damen PJJ, Kroese TE, van Hillegersberg R, et al. The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys . Nov 15 2021;111(4):936-948. doi:10.1016/j.ijrobp.2021.07.1695
5. Venkatesulu BP, Mallick S, Lin SH, Krishnan S. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol . Mar 2018;123:42-51. doi:10.1016/j.critrevonc.2018.01.003
6. Mallick S, V RA, Giridhar P, et al. A Systematic Review and Meta-analysis of the Impact of Radiation-Related Lymphopenia on Outcomes in High-Grade Gliomas. South Asian J Cancer . Oct 2022;11(4):361-369. doi:10.1055/s-0042-1753504
7. Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer . Jan 2020;20(1):12-25. doi:10.1038/s41568-019-0224-7
8. Audi ZF, Saker Z, Rizk M, et al. Immunosuppression in Medulloblastoma: Insights into Cancer Immunity and Immunotherapy.Curr Treat Options Oncol . Jul 30 2021;22(9):83. doi:10.1007/s11864-021-00874-9
9. Bockmayr M, Mohme M, Klauschen F, et al. Subgroup-specific immune and stromal microenvironment in medulloblastoma. Oncoimmunology . 2018;7(9):e1462430. doi:10.1080/2162402X.2018.1462430
10. Patel S, Wang S, Snuderl M, Karajannis MA. Pre-treatment lymphopenia and indication of tumor-induced systemic immunosuppression in medulloblastoma. J Neurooncol . Feb 2018;136(3):541-544. doi:10.1007/s11060-017-2678-3
11. Gajjar A, Robinson GW, Smith KS, et al. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol . Mar 1 2021;39(7):822-835. doi:10.1200/JCO.20.01372
12. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol . Oct 2006;7(10):813-20. doi:10.1016/S1470-2045(06)70867-1
13. Wang F, Cathcart SJ, DiMaio DJ, et al. Comparison of tumor immune environment between newly diagnosed and recurrent glioblastoma including matched patients. J Neurooncol . Aug 2022;159(1):163-175. doi:10.1007/s11060-022-04053-0
14. Turner CP, McLay J, Hermans IF, et al. Tumour infiltrating lymphocyte density differs by meningioma type and is associated with prognosis in atypical meningioma. Pathology . Jun 2022;54(4):417-424. doi:10.1016/j.pathol.2021.10.002
15. Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet . May 26 2018;391(10135):2128-2139. doi:10.1016/S0140-6736(18)30789-X
16. Bienkowski M, Preusser M. Prognostic role of tumour-infiltrating inflammatory cells in brain tumours: literature review. Curr Opin Neurol . Dec 2015;28(6):647-58. doi:10.1097/WCO.0000000000000251
17. Shadbad MA, Asadzadeh Z, Hosseinkhani N, et al. A Systematic Review of the Tumor-Infiltrating CD8(+) T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology. Front Immunol . 2021;12:734956. doi:10.3389/fimmu.2021.734956
18. Kmiecik J, Poli A, Brons NH, et al. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol . Nov 15 2013;264(1-2):71-83. doi:10.1016/j.jneuroim.2013.08.013
19. Mauldin IS, Jo J, Wages NA, et al. Proliferating CD8(+) T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma.Cells . Dec 1 2021;10(12)doi:10.3390/cells10123378
20. Safaei S, Mohme M, Niesen J, Schuller U, Bockmayr M. DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles. Oncoimmunology . 2021;10(1):1932365. doi:10.1080/2162402X.2021.1932365
21. Sharma R, Katiyar V, Gurjar H, Sharma M, Goda R, Vora Z. Is medulloblastoma associated with systemic immunomodulation? - A comparative analysis of preoperative inflammatory markers. Surg Neurol Int . 2020;11:86. doi:10.25259/SNI_336_2019
22. Grabovska Y, Mackay A, O’Hare P, et al. Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. Nat Commun . Aug 28 2020;11(1):4324. doi:10.1038/s41467-020-18070-y
23. Vermeulen JF, Van Hecke W, Adriaansen EJM, et al. Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma. Oncoimmunology . 2018;7(3):e1398877. doi:10.1080/2162402X.2017.1398877
24. Murata D, Mineharu Y, Arakawa Y, et al. High programmed cell death 1 ligand-1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma. J Neurosurg . Mar 2018;128(3):710-716. doi:10.3171/2016.11.JNS16991
25. Ebrahimi S, Lim G, Liu A, et al. Radiation-Induced Lymphopenia Risks of Photon Versus Proton Therapy for Esophageal Cancer Patients.Int J Part Ther . Fall 2021;8(2):17-27. doi:10.14338/IJPT-20-00086
26. Gaikwad U, Bajpai J, Jalali R. Combinatorial approach of immuno-proton therapy in cancer: Rationale and potential impact.Asia Pac J Clin Oncol . May 16 2023;doi:10.1111/ajco.13966
27. De B, Ng SP, Liu AY, et al. Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma . 2021;8:57-69. doi:10.2147/JHC.S282062
28. Cunningham D, Zaniletti I, Breen W, et al. Lymphopenia in Pediatric Patients Following Proton Radiotherapy. Int J Radiat Oncol Biol Phys . Nov 1 2021;111(3)(Supplement):e173.
29. Chou B, Hopper A, Elster J, et al. Volumetric de-escalation and improved acute toxicity with proton craniospinal irradiation using a vertebral body-sparing technique. Pediatr Blood Cancer . May 2022;69(5):e29489. doi:10.1002/pbc.29489
30. Ellis RE. The distribution of active bone marrow in the adult.Phys Med Biol . Jan 1961;5:255-8. doi:10.1088/0031-9155/5/3/302
31. Liu KX, Ioakeim-Ioannidou M, Susko MS, et al. A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. Int J Radiat Oncol Biol Phys . Mar 1 2021;109(3):726-735. doi:10.1016/j.ijrobp.2020.09.049